|Slideshows|October 13, 2016

4 Warning Signs of Illness Falsification

Medical, psychiatric, and/or developmental disorders can be falsified in a variety of ways. Know the warning signs often missed by clinicians.

To view the information in PDF format, click here.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

BySarah Cheema, MD,Andrew Canto, MD,Nicolas Badre, MD

July 21st 2026

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

ByGustavo Alva, MD, DFAPA,Ann Childress, MD

June 26th 2026

What Should Psychiatrists Know About Pediatric Sleep Apnea and Insomnia Treatment?

ByCarol Rosen, MD

June 22nd 2026

No Screens Before Bed: Teen Smartphone Use at Bedtime Predicts Overnight Phone Activity

ByLeah Kuntz,Gina M. Mathew, PhD

June 15th 2026

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

ByLeah Kuntz

June 8th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

4 Warning Signs of Illness Falsification

Related Content

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

Starting ADHD Treatment in Adolescents, With Ann Childress, MD

What Should Psychiatrists Know About Pediatric Sleep Apnea and Insomnia Treatment?

No Screens Before Bed: Teen Smartphone Use at Bedtime Predicts Overnight Phone Activity

“Engineered Addiction”: Redefining Addictive Disorders and the Psychiatric Impact of Social Media

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation

Future DSM Plans Overlook Core Problem of Validity

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

Crisis Management and Care Planning in Schizophrenia

Assessing Antipsychotics as Antidepressant Adjuncts